Purpose — to determine the relationships between the changes in functional parameters of vision that occur in primary open-angle glaucoma (POAG) patients on neuroprotective therapy. Material and methods. The study included 146 patients with stages I—III POAG aged 40 to 85 years. The patients were randomly divided into the study group and the control group at 2:1 ratio. All patients received traditional neuroprotective therapy. Patients of the study group were additionally treated with Retinalamine (№10, intramuscularly, one course). The patients were examined during the initial visit, then after 1 and 3 months; the examination included collection of anamnesis data, visometry, Maklakov tonometry, ophthalmoscopy, Förster white stimulus field of vision test, photostress test, and contrast sensitivity test. Results. Examination data are included in the analysis. In the setting of drug therapy, patients showed widening of the visual field, improvement of uncorrected visual acuity and contrast sensitivity, and reduction of photostress test recovery time. Direct correlation was found between Retinalamine use, and uncorrected visual acuity and contrast sensitivity; it also had negative correlation with photostress test result. No adverse events occurred during the course of the study. Conclusion. Retinalamin (Russia) has prolonged neuroprotective effect in glaucoma. The drug is most effective in glaucoma stages I A and II A.